▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Alnylam Pharmaceuticals (NASDAQ: ALNY)

$291.78

(2.3%)

$6.47

Price as of May 19, 2025, 3:58 p.m. ET

Alnylam Pharmaceuticals Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
ALNY	+95.35%	+103.46%	+15.26%	+4,647%
S&P	+12.45%	+100.69%	+14.95%	+432%

Alnylam Pharmaceuticals Company Info

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

News & Analysis

The Fool has written over 200 articles on Alnylam Pharmaceuticals.

Featured Article

Alnylam Delivers a Big Q4 Earnings Beat

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

JesterAI | Feb 13, 2025

Featured Article

SPDR S&P Biotech ETF (XBI): How to Buy

Rachel Warren | Jan 25, 2025

Alnylam's Revenues Drop Sharply in Q3

JesterAI | Oct 31, 2024

Alnylam Pharmaceuticals' product revenues grew at a healthy pace, but on other fronts, it struggled.

Alnylam Pharmaceuticals Outperformed in Q1

JesterAI | May 10, 2024

The rare disease specialist beat Wall Street's expectations with strong revenue growth and smaller-than-anticipated losses.

Why Alnylam Pharmaceuticals Stock Is Sinking Today

Keith Speights | Feb 15, 2024

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Top Biotech ETFs to Buy Now

Keith Speights | Nov 9, 2023

Here are the five best biotech ETFs to invest in right now.

2 Growth Stocks That Could Rocket Higher Before the End of 2023

Cory Renauer | Oct 8, 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

Why Alnylam Pharmaceuticals Topped the Market Today

Eric Volkman | Jul 17, 2023

Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.

Valuation

Podcast Episodes

20181212_IF_Healthcare_thumb_05

RNAi Goes Big-Time in 2018

A first-in-kind FDA approval catapulted this treatment approach into the spotlight.

Motley Fool Staff | Dec 18, 2018

Earnings Transcripts

Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript

ALNY earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Oct 29, 2021

Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Transcript

ALNY earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 3, 2021

Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript

ALNY earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | Apr 29, 2021

Alnylam Pharmaceuticals Inc (ALNY) Q4 2020 Earnings Call Transcript

ALNY earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 11, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services